<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192542</url>
  </required_header>
  <id_info>
    <org_study_id>CR-1636BE</org_study_id>
    <nct_id>NCT01192542</nct_id>
  </id_info>
  <brief_title>Pilot Evaluation of a New Galyfilcon A Lens Prototype and Enfilcon A Lens</brief_title>
  <official_title>Dispensing Evaluation of a New Galyfilcon A Prototype and Avaira Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the visual acuity, limbal and bulbar redness of the
      new galyfilcon A prototype lenses against Avaira® lenses when worn as daily wear for seven
      (7) days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monocular Visual Acuity Assessment</measure>
    <time_frame>Post lens insertion (baseline)</time_frame>
    <description>Snellen monocular visual acutity (VA) assessed by the Investigator and was converted to the LogMAR scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular Visual Acuity</measure>
    <time_frame>Post lens insertion (baseline)</time_frame>
    <description>Snellen binocular visual acuity assessed by the Investigator and was converted to the LogMAR scale. A value &lt;0 implies clinically positive results, a value &gt;0 implies clinically negative results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Limbal Redness of Grade 3 or Above</measure>
    <time_frame>After 6-8 days of lens wear</time_frame>
    <description>Limbal redness was assessed using a 5-point slit lamp classification scale (5-Worst, 0-None). Only those eyes with limbal redness grade &gt;= 3 were reported for purposes of this analysis. Grades 3 -5 are considered to be part of the adverse events reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bulbar Redness of Grade 3 or Above</measure>
    <time_frame>After 6-8 days of lens wear</time_frame>
    <description>Bulbar redness was assessed using a 5-point slit lamp classification scale (5-Worst, 0-None). Only those eyes with bulbar redness grade &gt;= 3 were reported for purposes of this analysis. Grades 3 -5 are considered to be part of the adverse events reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>galyfilcon A prototype lens/enfilcon A lens</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enfilcon A lens/galyfilcon A prototype lens</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>galyfilcon A prototype lens</intervention_name>
    <description>Prototype silicone hydrogel contact lens</description>
    <arm_group_label>galyfilcon A prototype lens/enfilcon A lens</arm_group_label>
    <arm_group_label>enfilcon A lens/galyfilcon A prototype lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>enfilcon A lens</intervention_name>
    <description>Marketed silicone hydrogel contact lens</description>
    <arm_group_label>galyfilcon A prototype lens/enfilcon A lens</arm_group_label>
    <arm_group_label>enfilcon A lens/galyfilcon A prototype lens</arm_group_label>
    <other_name>Avaira® contact lens</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is a current spherical soft contact lens wearer and willing to wear the
             study lenses on a daily wear basis for the duration of the study.

          -  The subject's optimal vertexed spherical equivalent distance correction must be
             between -1.00 and - 5.00D.

          -  Any cylinder power must be ≤ -0.75D.

          -  The subject must have visual acuity best correctable to 20/25+3 or better for each
             eye.

          -  The subject must read and sign the Statement of Informed Consent.

          -  The subject must appear able and willing to adhere to the instructions set forth in
             this clinical protocol.

        Exclusion Criteria:

          -  Ocular or systemic allergies or disease which might interfere with contact lens wear.

          -  Systemic disease or use of medication which might interfere with contact lens wear.

          -  Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal
             staining, or any other abnormalities of the cornea which would contraindicate contact
             lens wear.

          -  Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which
             might interfere with contact lens wear.

          -  Any ocular infection.

          -  Any corneal distortion resulting from previous hard or rigid gas permeable contact
             lens wear.

          -  Pregnancy or lactation.

          -  Diabetes.

          -  Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease
             (e.g. HIV).

          -  Habitual contact lens type is toric, multifocal, or is worn as extended wear.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fincastle</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>December 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 17, 2014</results_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 39 enrolled, with one screen failure prior to randomization, leaving 38 starting and completing the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Galyfilcon A Prototype Lens/Enfilcon A Lens</title>
          <description>The galyfilcon A prototype contact lens worn daily for 6-8 days first then the enfilcon A contact lens worn daily for 6-8 days second.</description>
        </group>
        <group group_id="P2">
          <title>Enfilcon A Lens/Galyfilcon A Prototype Lens</title>
          <description>The enfilcon A contact lens worn daily for 6-8 days first then the galyfilcon A prototype contact lens worn daily for 6-8 days second.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline summary was conducted on all enrolled subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects who enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Monocular Visual Acuity Assessment</title>
        <description>Snellen monocular visual acutity (VA) assessed by the Investigator and was converted to the LogMAR scale.</description>
        <time_frame>Post lens insertion (baseline)</time_frame>
        <population>Analysis was conducted on subjects who were enrolled, randomized, and successfully completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A Prototype Lens</title>
            <description>Prototype silicone hydrogel lens.</description>
          </group>
          <group group_id="O2">
            <title>Enfilcon A Lens</title>
            <description>Marketed silicone hydrogel lens.</description>
          </group>
        </group_list>
        <measure>
          <title>Monocular Visual Acuity Assessment</title>
          <description>Snellen monocular visual acutity (VA) assessed by the Investigator and was converted to the LogMAR scale.</description>
          <population>Analysis was conducted on subjects who were enrolled, randomized, and successfully completed the study.</population>
          <units>logMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.0317"/>
                    <measurement group_id="O2" value="-0.04" spread="0.0317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis is the monocular visual acuity of the galyfilcon A prototype lens is non-inferior to that of the enfilcon A lens.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin of 0.05 (1/2 LogMAR line) was used.</non_inferiority_desc>
            <param_type>Least-square mean difference</param_type>
            <param_value>-0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0064</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
            <estimate_desc>The mean difference is calculated as: Test lens - Control lens.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Limbal Redness of Grade 3 or Above</title>
        <description>Limbal redness was assessed using a 5-point slit lamp classification scale (5-Worst, 0-None). Only those eyes with limbal redness grade &gt;= 3 were reported for purposes of this analysis. Grades 3 -5 are considered to be part of the adverse events reporting.</description>
        <time_frame>After 6-8 days of lens wear</time_frame>
        <population>Analysis was conducted on subjects who successfully completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A Prototype Lens</title>
            <description>Prototype silicon hydrogel contact lens.</description>
          </group>
          <group group_id="O2">
            <title>Enfilcon A Lens</title>
            <description>Marketed silicone hydrogel lens.</description>
          </group>
        </group_list>
        <measure>
          <title>Limbal Redness of Grade 3 or Above</title>
          <description>Limbal redness was assessed using a 5-point slit lamp classification scale (5-Worst, 0-None). Only those eyes with limbal redness grade &gt;= 3 were reported for purposes of this analysis. Grades 3 -5 are considered to be part of the adverse events reporting.</description>
          <population>Analysis was conducted on subjects who successfully completed the study.</population>
          <units>Subject Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bulbar Redness of Grade 3 or Above</title>
        <description>Bulbar redness was assessed using a 5-point slit lamp classification scale (5-Worst, 0-None). Only those eyes with bulbar redness grade &gt;= 3 were reported for purposes of this analysis. Grades 3 -5 are considered to be part of the adverse events reporting.</description>
        <time_frame>After 6-8 days of lens wear</time_frame>
        <population>Analysis was conducted on subjects who successfully completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A Prototype Lens</title>
            <description>Prototype silicone hydrogel contact lens.</description>
          </group>
          <group group_id="O2">
            <title>Enfilcon A Lens</title>
            <description>Marketed silicone hydrogel contact lens.</description>
          </group>
        </group_list>
        <measure>
          <title>Bulbar Redness of Grade 3 or Above</title>
          <description>Bulbar redness was assessed using a 5-point slit lamp classification scale (5-Worst, 0-None). Only those eyes with bulbar redness grade &gt;= 3 were reported for purposes of this analysis. Grades 3 -5 are considered to be part of the adverse events reporting.</description>
          <population>Analysis was conducted on subjects who successfully completed the study.</population>
          <units>Subject Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Binocular Visual Acuity</title>
        <description>Snellen binocular visual acuity assessed by the Investigator and was converted to the LogMAR scale. A value &lt;0 implies clinically positive results, a value &gt;0 implies clinically negative results</description>
        <time_frame>Post lens insertion (baseline)</time_frame>
        <population>Analysis was conducted on subjects who enrolled, were randomized, and successfully complete the study per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Galyfilcon A Prototype Lens</title>
            <description>Prototype silicone hydrogel lens.</description>
          </group>
          <group group_id="O2">
            <title>Enfilcon A Lens</title>
            <description>Marketed silicone hydrogel lens.</description>
          </group>
        </group_list>
        <measure>
          <title>Binocular Visual Acuity</title>
          <description>Snellen binocular visual acuity assessed by the Investigator and was converted to the LogMAR scale. A value &lt;0 implies clinically positive results, a value &gt;0 implies clinically negative results</description>
          <population>Analysis was conducted on subjects who enrolled, were randomized, and successfully complete the study per protocol.</population>
          <units>LogMAR</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.032"/>
                    <measurement group_id="O2" value="-0.08" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis is the binocular visual acuity of the galyfilcon A prototype lens is non-inferior to that of the enfilcon A lens.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin of 0.05 (1/2 LogMAR line) was used.</non_inferiority_desc>
            <param_type>Least-square mean difference</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0091</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.018</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded when the subjects were exposed to the Investigational lenses.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>All subjects who exposed to the Investigation lenses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Pall, O.D., M.S. F.A.A.O. Principal Research Optometrist</name_or_title>
      <organization>Johnson and Johnson Vision Care</organization>
      <phone>1 904 443-1290</phone>
      <email>bpall@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

